Business / Finance

RSS

AMRI reports $50.2 million total revenue for third quarter 2011

...

9 Nov 2011

Mesa Labs declares regular quarterly dividend of $.13 per share

Mesa Laboratories, Inc. today announced that its Board of Directors has declared a regular quarterly dividend of $.13 per share of common stock, up from $.12 per share last quarter.

9 Nov 2011

AcelRx reports revenue of $408,000 for third quarter 2011

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results today for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

BioSpecifics reports $0.3M net income for third quarter 2011 vs. $0.5M net loss for third quarter 2010

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe today announced its financial results for the third quarter ended September 30, 2011 and provided a corporate update. For the quarter, the Company reported net income of $0.3 million or $0.04 per share on a basic and on a fully diluted basis.

9 Nov 2011

Fluidigm third quarter total revenue increases 25% to $10.6 million

Fluidigm Corporation today announced its financial results for the third quarter ended September 30, 2011.

9 Nov 2011

Inova Labs secures $17.5M in Series B round of equity financing

Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive Pulmonary Disease (COPD) market, announced today that it has secured a Series B round of equity financing for up to $17.5M from an investment syndicate led by Latterell Venture Partners, based in San Francisco, Calif.

9 Nov 2011

DFINE closes $25 million round of equity financing

DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced today the closing of a $25 million round of equity financing.

9 Nov 2011

Accuray reports total consolidated GAAP revenue of $100.5 million for first quarter 2012

Accuray Incorporated, the premier radiation oncology company, announced today financial results for the first quarter of fiscal 2012 that ended September 30, 2011.

9 Nov 2011

Electromed first quarter net revenues increase 29.1% to $5.38 million

Electromed, Inc. today announced financial results for the three-month period ended September 30, 2011. Net Revenues for the three months ended September 30, 2011 were approximately $5,379,000, a 29.1% increase compared to Net Revenues of approximately $4,165,000 for the same period last year.

8 Nov 2011

Bioject third quarter revenues increase to $3.1 million

Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, today reported financial results for the third quarter ended September 30, 2011.

8 Nov 2011

Antares Pharma third quarter total revenues increase 26% to $3.9M

Antares Pharma, Inc. today reported financial and operating results for the third quarter ended September 30, 2011.

8 Nov 2011

BioScrip third quarter revenue increases 2.9% to $454.0 million

BioScrip, Inc. today announced 2011 third quarter financial results. Revenue for the three months ended September 30, 2011 was $454.0 million and net income was $0.5 million, or $0.01 per diluted share, including $5.0 million in restructuring charges, severance and other employee costs.

8 Nov 2011

Comprehend Systems closes $1.2 million seed round funding

Driven by increasing demand from drug and medical device developers for cost-effective and user-friendly data analytics tools, Comprehend Systems, Inc. closed $1.2 million in seed round funding to support further development of Comprehend Clinical, its clinical data visualization and analytics software.

8 Nov 2011

Salix enters definitive agreement to acquire Oceana Therapeutics

Salix Pharmaceuticals, Ltd. and Oceana Therapeutics, LLC today announced that they have entered into a definitive agreement whereby Salix will acquire all of the outstanding stock of Oceana Therapeutics, Inc., a privately-held global provider of gastroenterology and urology therapeutics, for $300 million in cash.

8 Nov 2011

CardioNet third quarter revenue decreases 3.2% to $26.6 million

CardioNet, Inc., a leading wireless medical technology company with a current focus on the diagnosis and monitoring of cardiac arrhythmias, today reported results for the third quarter ended September 30, 2011.

8 Nov 2011

HUOH pays $3,500,000 in dividends to Ohio doctor owners/insureds in the last 40 months

HUOH is committed to its policyholders and their professional reputation by having a "zero tolerance" for nuisance claims and unparalleled aggressive defense programs for its physicians. Once again, continuing to build on its success from 2010, HUOH is attracting extraordinary physicians, managing claims exceptionally and now delivering another dividend to its' Ohio physician owners of $1,000,000.

8 Nov 2011

Medidata third quarter revenues increase 13% to $46.3 million

Medidata Solutions, a leading global provider of SaaS-based clinical technology solutions that enhance the efficiency of clinical development, today announced its financial results for the third quarter 2011, as well as provided financial guidance for the fourth quarter and full year 2011.

8 Nov 2011

CHS commences cash tender offer for 8⅞% Senior Notes due 2015

Community Health Systems, Inc. today announced that its wholly-owned subsidiary, CHS/Community Health Systems, Inc., has commenced a cash tender offer for up to $1.0 billion of the Issuer's approximately $2.8 billion aggregate principal amount outstanding of its 8⅞% Senior Notes due 2015 on the terms and subject to the conditions set forth in the Issuer's Offer to Purchase dated November 7, 2011.

8 Nov 2011

EpiCept reports net loss of $5.4 million for third quarter 2011

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2011, and provided an update with respect to the Company's key business initiatives.

8 Nov 2011

Quintiles closes agreement to acquire Advion BioServices

Quintiles' ability to provide customers with actionable early-stage data to make better development decisions faster has taken a significant step forward with the closing of the previously announced agreement to acquire Advion BioServices, a premier U.S.-based bioanalytical laboratory.

From Advion 7 Nov 2011